Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.
Abstract: The intersection of medicine and engineering holds significant promise for advancing cancer treatment. Traditional chemotherapy, which typically employs maximum tolerable doses, often leads ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback